Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID-19 in chronic lymphocytic leukaemia?
BTK
IRF7
SARS-CoV-2
TLR7
X-linked agammaglobulinemia
toll-like receptor 7
Journal
Scandinavian journal of immunology
ISSN: 1365-3083
Titre abrégé: Scand J Immunol
Pays: England
ID NLM: 0323767
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
revised:
22
02
2022
received:
10
02
2022
accepted:
22
02
2022
pubmed:
5
3
2022
medline:
5
4
2022
entrez:
4
3
2022
Statut:
ppublish
Résumé
Infections with SARS-CoV-2 have been unduly severe in patients with haematological malignancies, in particular in those with chronic lymphocytic leukaemia (CLL). Based on a series of observations, we propose that an underlying mechanism for the aggressive clinical course of COVID-19 in CLL is a paucity of plasmacytoid dendritic cells (pDCs) in these patients. Indeed, pDCs express Toll-like receptor 7 (TLR7), which together with interferon-regulatory factor 7 (IRF7), enables pDCs to produce large amounts of type I interferons, essential for combating COVID-19. Treatment of CLL with Bruton's tyrosine kinase (BTK) inhibitors increased the number of pDCs, likely secondarily to the reduction in the tumour burden.
Identifiants
pubmed: 35244285
doi: 10.1111/sji.13153
pmc: PMC9115357
doi:
Substances chimiques
IRF7 protein, human
0
Interferon Regulatory Factor-7
0
Toll-Like Receptor 7
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13153Subventions
Organisme : This work was supported by Cancerfonden
Informations de copyright
© 2022 The Authors. Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of The Scandinavian Foundation for Immunology.
Références
Leuk Res. 2021 Mar;102:106520
pubmed: 33611131
Science. 1999 Jun 11;284(5421):1835-7
pubmed: 10364556
J Exp Med. 2013 Nov 18;210(12):2515-22
pubmed: 24145513
Front Immunol. 2021 Jun 10;12:689472
pubmed: 34177947
Semin Immunopathol. 2019 Mar;41(2):153-164
pubmed: 30276444
Clin Immunol. 2021 Sep;230:108816
pubmed: 34352390
Curr Opin Allergy Clin Immunol. 2021 Dec 1;21(6):525-534
pubmed: 34596095
Nature. 1993 Jan 21;361(6409):226-33
pubmed: 8380905
Leukemia. 2022 Feb;36(2):476-481
pubmed: 34564699
Leukemia. 2014 Oct;28(10):2005-15
pubmed: 24721775
Scand J Immunol. 2022 Apr;95(4):e13153
pubmed: 35244285
Front Immunol. 2017 Feb 10;8:108
pubmed: 28239379
PLoS One. 2018 Apr 13;13(4):e0195313
pubmed: 29652910
Lancet Rheumatol. 2022 Jan;4(1):e33-e41
pubmed: 34806036
J Clin Oncol. 2013 Jan 1;31(1):88-94
pubmed: 23045577
Sci Immunol. 2018 Jan 26;3(19):
pubmed: 29374079
Front Immunol. 2021 Jul 19;12:694853
pubmed: 34349760
Cancer Res. 2003 Aug 1;63(15):4497-506
pubmed: 12907623
Nature. 2022 Mar;603(7902):587-598
pubmed: 35090163
Annu Rev Immunol. 2005;23:275-306
pubmed: 15771572
Blood. 2020 Sep 3;136(10):1134-1143
pubmed: 32688395
Science. 2006 Jun 16;312(5780):1669-72
pubmed: 16709748
Hemasphere. 2021 Apr 26;5(5):e564
pubmed: 33912812
Blood. 2020 May 21;135(21):1912-1915
pubmed: 32302379
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Scand J Immunol. 2002 Nov;56(5):518-21
pubmed: 12410802
J Leukoc Biol. 2003 Dec;74(6):1125-38
pubmed: 12960254
J Allergy Clin Immunol. 2020 Jul;146(1):211-213.e4
pubmed: 32333914
Br J Haematol. 2018 Oct;183(2):212-224
pubmed: 30125946
N Engl J Med. 2013 Jul 4;369(1):32-42
pubmed: 23782158
Sci Immunol. 2021 Aug 19;6(62):
pubmed: 34413140
Front Immunol. 2021 Nov 11;12:756262
pubmed: 34858409
EBioMedicine. 2021 Dec;74:103705
pubmed: 34861491
JAMA. 2020 Aug 18;324(7):663-673
pubmed: 32706371
J Exp Med. 2001 Sep 17;194(6):863-9
pubmed: 11561001
Leukemia. 2021 Dec;35(12):3444-3454
pubmed: 34725454
Front Cell Dev Biol. 2021 Mar 11;9:630942
pubmed: 33777941
Nat Commun. 2018 Aug 30;9(1):3525
pubmed: 30166549
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303